While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...

Medicines and chemicals are huge exports for European Union countries. That makes the sector a weak spot as trade tensions ...

European Central Bank President Christine Lagarde said on Wednesday U.S. tariffs could have a disinflationary impact in ...

The pharma has five listed studies running for the asset under the CORALreef program. Merck is developing enlicitide decanoate in partnership with UCB Pharmaceuticals. Meanwhile, efinopegdutide is ...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this ...

A clear trend has emerged from the data: nearly all the ‘winners’ are in the pharmaceutical or related fields. The 4th annual LinkedIn Top Companies ranking features the 25 best employers to develop ...

The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S ...

President Donald Trump said at an event Tuesday that "a major tariff" was coming to the pharmaceutical industry. The sector was exempted from the sweeping tariffs that were announced last week and ...

President Donald Trump on Tuesday (Apr 8) said the United States will soon announce a "major" tariff on pharmaceutical imports. Speaking at an event at the National Republican Congressional ...

President Donald Trump appears to be making good on his threats to the pharma industry, announcing on Tuesday that “major” tariffs are coming, in an attempt to force companies to move their ...

Trump’s sweeping reciprocal tariffs, unveiled on April 2, include duties of 20% on the EU but appear to have excluded pharmaceuticals. Nevertheless, pharmaceutical-specific tariffs look to be a ...

France 2030 validates 4Moving Biotech's scientific ... market launch by 2030 4Moving Biotech (4MB), a spin-off of 4P-Pharma developing the first potential disease-modifying drug (DMOAD) for ...